Inmaculada Puertas
YOU?
Author Swipe
View article: Immunological Monitoring During Anti-CD20 Therapies to Predict Infection Risk and Treatment Response in Multiple Sclerosis Patients
Immunological Monitoring During Anti-CD20 Therapies to Predict Infection Risk and Treatment Response in Multiple Sclerosis Patients Open
Background: Immunological monitoring in multiple sclerosis (MS) patients treated with disease-modifying drugs may help predict infectious complications and guide treatment. The main objective of this study was to evaluate whether anti-CD20…
View article: Immune checkpoint-based biomarkers for therapeutic response in patients with multiple sclerosis
Immune checkpoint-based biomarkers for therapeutic response in patients with multiple sclerosis Open
Introduction Although numerous disease-modifying treatments have been introduced for multiple sclerosis (MS), approximately 25% of patients experience therapeutic failure. This underscores the urgent need for reliable, minimally invasive b…
View article: Extracellular Vesicles as Novel Biomarkers for Tumor Association in Intermediate-Risk Paraneoplastic Neurologic Syndromes
Extracellular Vesicles as Novel Biomarkers for Tumor Association in Intermediate-Risk Paraneoplastic Neurologic Syndromes Open
This study provides Class IV evidence that higher circulating blood levels of EVs can distinguish between tumor-associated PNS from suspected PNS without tumor.
View article: Extracellular Vesicle-Derived MicroRNAs as a Biomarker for Therapeutic Response in Multiple Sclerosis
Extracellular Vesicle-Derived MicroRNAs as a Biomarker for Therapeutic Response in Multiple Sclerosis Open
This study underscores the potential of specific EV characteristics and microRNA content as early biomarkers for treatment response in patients with MS. The downregulation of specific microRNAs emerges as a promising indicator of favorable…
View article: 20811. MICROARN CONTENIDOS EN VESÍCULAS EXTRACELULARES CIRCULANTES COMO BIOMARCADORES MOLECULARES DE RESPUESTA AL TRATAMIENTO DE ESCLEROSIS MÚLTIPLE
20811. MICROARN CONTENIDOS EN VESÍCULAS EXTRACELULARES CIRCULANTES COMO BIOMARCADORES MOLECULARES DE RESPUESTA AL TRATAMIENTO DE ESCLEROSIS MÚLTIPLE Open
View article: 20328. ALTERACIONES EN LA EXPRESIÓN DE MOLÉCULAS REGULADORAS EN CÉLULAS B: IMPLICACIONES EN LA PROGRESIÓN DE LA DISCAPACIDAD EN ESCLEROSIS MÚLTIPLE
20328. ALTERACIONES EN LA EXPRESIÓN DE MOLÉCULAS REGULADORAS EN CÉLULAS B: IMPLICACIONES EN LA PROGRESIÓN DE LA DISCAPACIDAD EN ESCLEROSIS MÚLTIPLE Open
View article: 20236. IDENTIFICACIÓN DE CANDIDATOS A TRATAMIENTO DE ALTA EFICACIA EN ESCLEROSIS MÚLTIPLE A TRAVÉS DE LA CARACTERIZACIÓN INMUNOFENOTÍPICA DEL SISTEMA INMUNITARIO
20236. IDENTIFICACIÓN DE CANDIDATOS A TRATAMIENTO DE ALTA EFICACIA EN ESCLEROSIS MÚLTIPLE A TRAVÉS DE LA CARACTERIZACIÓN INMUNOFENOTÍPICA DEL SISTEMA INMUNITARIO Open
View article: 20967. TRATAMIENTO DE LA ESCLEROSIS MÚLTIPLE CON OCRELIZUMAB Y RITUXIMAB: MONITORIZACIÓN INMUNOLÓGICA A LARGO PLAZO PARA EVALUAR EL RIESGO DE INFECCIONES Y LA RESPUESTA AL TRATAMIENTO
20967. TRATAMIENTO DE LA ESCLEROSIS MÚLTIPLE CON OCRELIZUMAB Y RITUXIMAB: MONITORIZACIÓN INMUNOLÓGICA A LARGO PLAZO PARA EVALUAR EL RIESGO DE INFECCIONES Y LA RESPUESTA AL TRATAMIENTO Open
View article: 20324. EXPRESIÓN DE MOLÉCULAS DE PUNTOS DE CONTROL INMUNITARIO COMO BIOMARCADORES DE RESPUESTA AL TRATAMIENTO EN PACIENTES CON ESCLEROSIS MÚLTIPLE
20324. EXPRESIÓN DE MOLÉCULAS DE PUNTOS DE CONTROL INMUNITARIO COMO BIOMARCADORES DE RESPUESTA AL TRATAMIENTO EN PACIENTES CON ESCLEROSIS MÚLTIPLE Open
View article: Differential Protein Expression in Extracellular Vesicles Defines Treatment Responders and Non-Responders in Multiple Sclerosis
Differential Protein Expression in Extracellular Vesicles Defines Treatment Responders and Non-Responders in Multiple Sclerosis Open
Multiple sclerosis (MS) remains the leading cause of neurological disability among young adults worldwide, underscoring the urgent need to define the best therapeutic strategy. Recent advances in proteomics have deepened our understanding …
View article: Automatic evaluation of the Nine-Hole Peg Test in multiple sclerosis patients using machine learning models
Automatic evaluation of the Nine-Hole Peg Test in multiple sclerosis patients using machine learning models Open
Neurological damage in Multiple Sclerosis (MS) affects the motor, sensory, visual, cognitive and sphincteric systems, resulting in different degrees of disability. Upper limb dysfunction is a core deficit affecting MS patients. However, si…
View article: Antibody Content against Epstein–Barr Virus in Blood Extracellular Vesicles Correlates with Disease Activity and Brain Volume in Patients with Relapsing–Remitting Multiple Sclerosis
Antibody Content against Epstein–Barr Virus in Blood Extracellular Vesicles Correlates with Disease Activity and Brain Volume in Patients with Relapsing–Remitting Multiple Sclerosis Open
We aimed to analyze whether EVs carry antibodies against EBV antigens and the possibility that they could serve as diagnostic and disease activity blood biomarkers in RRMS. This was a prospective and observational study including patients …
View article: Dual role of peripheral B cells in multiple sclerosis: emerging remote players in demyelination and novel diagnostic biomarkers
Dual role of peripheral B cells in multiple sclerosis: emerging remote players in demyelination and novel diagnostic biomarkers Open
Introduction Multiple sclerosis is an inflammatory and demyelinating disease caused by a pathogenic immune response against the myelin sheath surfaces of oligodendrocytes. The demyelination has been classically associated with pathogenic B…
View article: Brain and immune system-derived extracellular vesicles mediate regulation of complement system, extracellular matrix remodeling, brain repair and antigen tolerance in Multiple sclerosis
Brain and immune system-derived extracellular vesicles mediate regulation of complement system, extracellular matrix remodeling, brain repair and antigen tolerance in Multiple sclerosis Open
Neural-derived and immune-derived EVs found in blood appear to be good specific biomarkers in MS for reflecting the disease state.
View article: Potential Roles of Extracellular Vesicles as Biomarkers and a Novel Treatment Approach in Multiple Sclerosis
Potential Roles of Extracellular Vesicles as Biomarkers and a Novel Treatment Approach in Multiple Sclerosis Open
Extracellular vesicles (EVs) are a heterogeneous group of bilayer membrane-wrapped molecules that play an important role in cell-to-cell communication, participating in many physiological processes and in the pathogenesis of several diseas…
View article: Frequency and Characterization of Movement Disorders in Anti-IgLON5 Disease
Frequency and Characterization of Movement Disorders in Anti-IgLON5 Disease Open
Objective: Anti-IgLON5 disease is a recently described neurological disease that shares features of autoimmunity and neurodegeneration. Abnormal movements appear to be frequent and important but have not been characterized and are under-re…
View article: Non-inflammatory causes of emergency consultation in patients with multiple sclerosis
Non-inflammatory causes of emergency consultation in patients with multiple sclerosis Open
View article: Causas no inflamatorias de consulta urgente en esclerosis múltiple
Causas no inflamatorias de consulta urgente en esclerosis múltiple Open
Describir consultas urgentes de pacientes con esclerosis múltiple (EM) distintas a brotes: causas, dificultades diagnósticas, características clínicas y tratamientos empleados. Estudio retrospectivo de los pacientes que acudieron a un Hosp…
View article: Clinical manifestations of the anti-IgLON5 disease
Clinical manifestations of the anti-IgLON5 disease Open
Patients with IgLON5 antibodies develop a characteristic sleep disorder preceded or accompanied by bulbar symptoms, gait abnormalities, oculomotor problems, and, less frequently, cognitive decline. IgG4 subclass antibodies predominate over…
View article: Neuromyelitis optica spectrum disorders
Neuromyelitis optica spectrum disorders Open
In patients with AQP4-IgG, the similar outcomes regardless of the clinical phenotype support the unified term NMOSD; nonwhite ethnicity and older age at onset are associated with worse outcome. Double-seronegative and AQP4-IgG-seropositive…
View article: Differential glatiramer acetate treatment persistence in treatment-naive patients compared to patients previously treated with interferon
Differential glatiramer acetate treatment persistence in treatment-naive patients compared to patients previously treated with interferon Open
Glatiramer acetate was safe and useful with low rates of serious adverse events and low rates of break-through disease. Injection intolerance proved a major limitation to glatiramer acetate use. Patients who had been previously treated wit…